Skip to main content

PRe-clinicAl studies of a PSA-based human vaccine candidate targeting visceral, cutaneOus and mucocutaneous Leishmaniasis and Development of the associated procedures for further clinical trials

Objective

The global aim of RAPSODI is : · to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). · to establish all the associated procedures required for the subsequent clinical trials, such as the selection of the appropriate patients and assessment of vaccine efficiency. For that purpose, an international consortium constituted of countries from endemic areas (India, Peru, Tunisia, Spain and France) and embracing multi-disciplinary approaches has been set-up. Based on successful results on VL dogs, the best VL animal model to date, RAPSODI will propose a second generation human-compatible vaccine candidate and confirm its activity in pre-clinical studies. As the chosen antigen is common to most, if not all, Leishmania species, an ambitious universal immunoprotective response is being sought. RAPSODI will also address the question of population selection in order to ascertain relevant and meaningful clinical trials and vaccination campaigns. Indeed, resistant individuals, when involved in either vaccinated or placebo groups, represent important bias to the analysis of the results. RAPSODI will investigate further the parasitological, immunological and genetic features of such clinical status, and will subsequently apply the generated knowledge to the development of assays and field tests, which represent stand-alone results. The package (vaccine candidate + diagnostic/prognostic tools) proposed by RAPSODI represents a global solution, and as such is believed to have a real impact on the worldwide leishmaniasis problem.

Field of science

  • /agricultural sciences/animal and dairy science/pets

Call for proposal

FP7-HEALTH-2007-B
See other projects for this call

Funding Scheme

CP-SICA - Collaborative project for specific cooperation actions dedicated to international cooperation partner countries (SICA)

Coordinator

VIRBAC SA
Address
Rue 13Eme Lid
06511 Carros
France
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 565 024,60
Administrative Contact
Cherifa Hemadou (Ms.)

Participants (8)

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
France
EU contribution
€ 404 093
Address
Boulevard De Dunkerque 44 Cs 90009
13572 Marseille
Activity type
Research Organisations
Administrative Contact
Ariel Crozon (Ms.)
INSTITUTO DE SALUD CARLOS III
Spain
EU contribution
€ 554 300,80
Address
Monforte De Lemos 5
28029 Madrid
Activity type
Research Organisations
Administrative Contact
Inmaculada Pastor (Ms.)
INDIAN COUNCIL OF MEDICAL RESEARCHSOCIETY
India
EU contribution
€ 330 840
Address
Ansari Nagar
110029 New Delhi
Activity type
Research Organisations
Administrative Contact
Sunita Saxena (Dr.)
UNIVERSIDAD PERUANA CAYETANO HEREDIA
Peru
EU contribution
€ 444 351,70
Address
Honorio Delgado 430
31 Lima
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Oscar Situ (Dr.)
INSTITUT PASTEUR DE TUNIS
Tunisia
EU contribution
€ 300 175,70
Address
Place Pasteur 13
1002 Tunis
Activity type
Research Organisations
Administrative Contact
Faycal Chaabane (Mr.)
AYMING
France
EU contribution
€ 90 680
Address
185 Avenue Des Gresillons
92622 Gennevilliers Cedex
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frederic Peyrane (Dr.)
INSTIMED

Participation ended

France
EU contribution
€ 4 500
Address
Rue Joseph Cugnot, Levée De Rochepinard
37702 Saint Pierre Des Corps
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jean-Michel Bousquet (Mr.)
SYNCROSOME SAS
France
EU contribution
€ 43 183,20
Address
Avenue De Luminy - Luminy Biotech Cp 908 163
13288 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Richard Mitry (Dr.)